Stockwinners Market Radar for June 28, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT MingZhu Logistics Holdings Ltd trading halted, news pending

19:50 EDT Dare Bioscience Inc trading halted, news pending

18:08 EDT PowerSchool CEO sells 24,409 class A shares - In a regulatory filing, PowerSchool CEO Hardeep Gulati disclosed the sale of 24,409 class A common shares of the company on June 27 at a price of $22.35 per share.

17:34 EDT Moog awarded $160M Navy contract - Moog was awarded $160M for a firm-fixed-price, long-term contract for the repair of swashplates, elevators, and flaperons in support of the V-22 aircraft. This is a three-year contract with no option periods, and work will be completed by June 2027. No funding will be obligated at the time of award. Individual delivery orders will be funded with appropriate fiscal year working capital funds (Navy) at the time of their issuance, and funds will not expire at the end of the current fiscal year. One company was solicited for this sole-source requirement pursuant to the authority set forth in 10 U.S. Code 2304, with one offer received. Naval Supply Systems Command Weapon Systems Support is the contracting activity.

17:04 EDT Walmart CEO sells 29,124 common shares - In a regulatory filing, Walmart president and CEO Douglas McMillon disclosed the sale of 29,124 common shares of the company on June 27 at a price of $68.3851 per share.

17:01 EDT Goldman Sachs plans to raise quarterly dividend to $3.00 from $2.75 per share - On Wednesday, June 26, the Federal Reserve notified the firm of the Stress Capital Buffer for The Goldman Sachs Group, of 6.4%, resulting in a Standardized Common Equity Tier 1 ratio requirement of 13.9%, which will become effective on October 1, 2024. "This increase does not seem to reflect the strategic evolution of our business and the continuous progress we've made to reduce our stress loss intensity, which the Federal Reserve had recognized in the last three tests. We will engage with our regulator to better understand their determinations," said Chairman and CEO David Solomon. "We continue to be well-positioned to support our clients as they navigate the challenges of a dynamic market environment. Our capital management philosophy prioritizes investing in our world-class interconnected businesses at accretive returns while prudently navigating the economic, regulatory, and geopolitical landscape." The firm's capital plan includes an increase in the common stock dividend from $2.75 to $3.00 per share beginning July 1, 2024, demonstrating confidence in the durability of our franchise. This increase is subject to approval by the firm's Board of Directors at the customary third quarter meeting.

16:46 EDT Mister Car Wash announces COO Mayra Chimienti resigns - In a regulatory filing, Mister Car Wash disclosed that on June 24, Mayra Chimienti, COO, resigned from her position with the company. Chimienti is expected to remain employed with, and provide transition services to, the company through December 31, 2024.

16:38 EDT PNC Financial says Stress Capital Buffer 2.2%, to recommend 3% dividend hike - The PNC Financial Services Group this week received the results of the Federal Reserve's 2024 Comprehensive Capital Analysis and Review. The Federal Reserve's CCAR disclosure included its estimate of PNC's minimum capital ratios for the period from the first quarter of 2024 through the first quarter of 2026 under the hypothetical Supervisory Severely Adverse scenario. Based on PNC's strong results, PNC's calculated Stress Capital Buffer for the four-quarter period beginning Oct. 1, 2024 is 2.2%, which is below the regulatory minimum SCB amount, resulting in an SCB of 2.5%. This is consistent with PNC's SCB in effect through Sept. 30, 2024. PNC's Common Equity Tier 1 ratio of 10.1% as reported for March 31, 2024 significantly exceeds the regulatory minimum plus our SCB, reflecting our strong capital levels. Furthermore, under the Federal Reserve's projections in the 2024 Supervisory Severely Adverse scenario, PNC's post-stress capital ratios are projected to remain well above regulatory minimums, with our minimum and ending CET1 ratios both projected to be 8.3%, compared to the regulatory minimum of 4.5%. PNC plans to recommend to its board of directors an increase in the quarterly cash dividend on common stock of 5 cents per share, or 3%, to $1.60 per share in the third quarter of 2024, consistent with the current capital plan approved by its board. PNC's board of directors is expected to consider this recommendation at its next scheduled meeting on July 2, 2024. Consistent with the SCB framework, which allows for capital returns in amounts in excess of the SCB minimum levels, our board of directors has authorized a repurchase framework under the previously approved repurchase program of up to 100 million common shares, of which approximately 44% were still available for repurchase at March 31, 2024. Share repurchase activity in the third quarter 2024 is expected to be consistent with recent quarterly share repurchase levels. PNC continues to evaluate and may adjust share repurchase activity, as actual amounts and timing are dependent on market and economic conditions as well as other factors. PNC's common share repurchases may be executed in privately negotiated transactions or through the open market, including under Rule 10b5-1 plans.

16:37 EDT BNY Mellon to increase quarterly dividend 12% to 47c per share - BNY Mellon announced its intention to increase its quarterly cash dividend on its common shares by 12% from 42c to 47c per share, commencing as early as the third quarter, subject to approval by the company's board of directors. The Federal Reserve released the results of its 2024 bank stress test. The Federal Reserve also notified the company that its preliminary Stress Capital Buffer, or SCB, requirement will remain 2.5%, equal to the regulatory floor. This SCB is expected to be effective from October 1, 2024, to September 30, 2025. The company continues to be authorized to repurchase common shares under its existing share repurchase program approved by the board, as announced in January 2023 and April.

16:36 EDT Fifth Third says preliminary stress capital buffer 3.2% - Fifth Third Bancorp released its preliminary stress capital buffer requirement resulting from the Federal Reserve Board's annual bank stress test. Fifth Third's preliminary stress capital buffer under the FRB severely adverse scenario is 3.2%, effective October 1, 2024. Fifth Third's Common Equity Tier 1 ratio at March 31, 2024 of 10.5% significantly exceeds the regulatory minimum of 4.5% plus the stress capital buffer, reflecting strong capital levels. In September, Fifth Third intends to recommend to its Board of Directors a 2 cent per share increase to the quarterly cash dividend on its common stock, consistent with its planned capital actions submitted to the Federal Reserve. Additionally, Fifth Third may elect to repurchase shares consistent with its publicly stated CET1 target of 10.5%. All future capital actions are subject to evaluation of Fifth Third's performance, the state of the economic environment, market conditions, regulatory factors, other risks and uncertainties, and approval by the Board of Directors.

16:35 EDT NaaS regains compliance with Nasdaq - NaaS announced that it has received a notification letter from Nasdaq informing the company that it has regained compliance with the Nasdaq Listing Rule 5550.

16:33 EDT State Street raises quarterly dividend to 76c per share, completes stress test - State Street announced its intention to increase its per share common stock dividend by 10% to 76c in the third quarter of 2024, subject to consideration and approval by its board. State Street continues to be authorized to repurchase common shares under its existing share repurchase program previously approved by its board. The company also announced that it had completed the Federal Reserve's 2024 Comprehensive Capital Analysis and Review, or CCAR, stress test process. State Street's calculated Stress Capital Buffer under this year's supervisory stress test was well below the 2.5% minimum, preliminarily resulting in a continued SCB at that floor, which maintains its common equity tier 1 ratio requirement at 8%. The Federal Reserve will release the firm's final SCB requirement by August 31, which will become effective on October 1 and remain in effect through September 30, 2025.

16:33 EDT Citi raises quarterly dividend to 56c per share from 53c - Citi announced that it has completed the Federal Reserve Board's 2024 annual supervisory stress test process. Citi's indicative Stress Capital Buffer ("SCB") requirement is 4.1%, down from the current 4.3%, and Citi's preliminary Standardized Common Equity Tier 1 (CET1) capital ratio regulatory requirement is 12.1%, down from the current 12.3%, effective October 1, 2024. As of March 31, 2024, Citi's Standardized CET1 capital ratio, which includes a 100-basis-point internal management buffer, stood at 13.5%, above the new regulatory requirement. The Federal Reserve Board will provide the Firm with its final SCB requirement by August 31, 2024, and that requirement will become effective on October 1, 2024, and will remain in effect until September 30, 2025. Citi's planned capital actions include an increase of Citi's quarterly common stock dividend from $0.53 to $0.56 per share, subject to quarterly approval by Citi's Board of Directors, starting in the third quarter of 2024. Citi will continue to assess share repurchases on a quarter-to-quarter basis.

16:31 EDT Capital One reports preliminary Stress Capital Buffer Requirement 5.5% - Capital One Financial announced the company's preliminary Stress Capital Buffer Requirement, as calculated by the Federal Reserve 2024 Comprehensive Capital Analysis and Review process, is 5.5%, effective October 1, 2024. Capital One's previously disclosed SCB of 4.8%, as calculated by the Board of Governors of the Federal Reserve System 2023 CCAR process, will remain in effect through the end of the third quarter of 2024.

16:18 EDT Project Energy Reimagined says business combination to close early July 2024 - Project Energy Reimagined Acquisition Corp. announced that its proposed business combination pursuant to the Business Combination Agreement, dated as of October 2, 2023, by and among PERAC, Heramba Electric plc, Heramba Merger Corp., Heramba Limited and Heramba GmbH, is anticipated to close in early July 2024, subject to the satisfaction or waiver of all applicable closing conditions.

16:16 EDT Kite Realty Group Trust upgraded by S&P to BBB with stable outlook - Kite Realty Group Trust announced that S&P Ratings upgraded its issuer credit rating for Kite Realty Group Trust and the Company's Operating Partnership, Kite Realty Group L.P., to 'BBB' from 'BBB-', with a stable outlook. In its public announcement on the matter, S&P cited "Kite Realty Group Trust has further deleveraged its balance sheet following its merger with RPAI" and noted "the Company will likely improve its leased occupancy and rents over the next couple of years due to our view that demand for its well-located, open-air centers will remain healthy amid limited supply in some markets."

16:09 EDT Bite Acquisition, Above Food complete business combination - Above Food and Bite Acquisition (BITE) announced the completion of their previously announced business combination. The business combination was approved at a special meeting of Above Food shareholders on June 7 and a special meeting of Bite's stockholders on April 29, and it closed on June 28. The common shares and warrants of the combined company, Above Food Ingredients are expected to begin trading on the Nasdaq under the ticker symbols "ABVE" and "ABVE.W", respectively, on July 1. The company sees a $200B-plus total addressable market opportunity "across key plant-based substitute categories and other adjacencies, fueled by favorable macroeconomic tailwinds, including rising food insecurity and increasing supply chain risks."

16:06 EDT SAITECH announces signing of MOU with Al-Farabi Kazakh National University - SAITETCH announced the signing of a Memorandum of Understanding with Al-Farabi Kazakh National University in the Republic of Kazakhstan. This collaboration aims to bolster educational and scientific research initiatives in the region. The MoU signifies a collaborative effort between SAI.TECH and the University spanning humanities, social sciences, and natural sciences. It includes exchanges of faculty and administrative staff, educational training programs for educators, and opportunities for student exchanges at both undergraduate and graduate levels, facilitating research internships and specialized training. At the core of this partnership is the establishment of joint educational programs and curricula, including initiatives for double diplomas, designed to enrich academic exchange and foster collaboration between the two entities. Additionally, the collaboration encompasses joint research projects, participation in state and international grants, and the publication of scientific materials in partner institutions' periodicals. This collaboration marks a significant milestone in SAI.TECH's expansion into Kazakhstan, leveraging its AI computing technology and expertise in sustainable computing with distributed energy solutions. SAI.TECH is committed to supporting the region's development in computing and beyond.

15:59 EDT Cassava Sciences says Dr. Wang had no involvement in Phase 3 simufilam trials - Cassava Sciences released the following statement: "Cassava Sciences reported it has learned today that a federal grand jury returned an indictment charging Hoau-Yan Wang for allegedly defrauding the U.S. National Institutes of Health. Hoau-Yan Wang was a tenured medical professor at a public university's medical school as well as a former paid science advisor to Cassava Sciences. According to public court documents, Dr. Wang engaged in illegal behavior to defraud the government through grant applications made to the NIH, resulting in the award of approximately $16 million in grants approximately 2017 to 2021 on behalf of himself and the Company. Wang's work under these grants was related to the early development phases of the Company's drug candidate and diagnostic test and how these were intended to work. Dr. Wang and his former public university medical school have had no involvement in the Company's Phase 3 clinical trials of simufilam. Simufilam is the Company's lead drug candidate proposed for treatment of Alzheimer's disease."

13:58 EDT Cassava continues selloff, shares now down 50% to $9.56

13:51 EDT Cassava sinks 36% to $12.16 after DOJ charges co-developer of drug

13:34 EDT Cassava Sciences trading resumes

13:16 EDT Kite Realty Group credit ratings raised by S&P Global - S&P Global Ratings raised its issuer credit ratings on Kite Realty Group to "BBB" from "BBB-" and its issue-level rating on the company's unsecured debt to "BBB" from "BBB-." Kite has further deleveraged its balance sheet following the merger with RPAI, said S&P, which expects its debt to EBITDA will remain in the "low-5x area" on a sustained basis.

13:01 EDT Baker Hughes reports U.S. rig count down 7 to 581 rigs

12:45 EDT Ads-Tec Energy PLC trading resumes

12:37 EDT Bit Origin Ltd trading resumes

12:27 EDT Bit Origin Ltd trading halted, volatility trading pause

12:19 EDT Westamerica names Anela Jonas as CFO, effective June 27 - In a regulatory filing, Westamerica Bancorporation said that effective June 27, it appointed Anela Jonas as CFO. Jonas is a California licensed certified public accountant who has performed a variety of responsibilities in the company's Finance and Administration Division for thirteen years, including serving as Controller. Effective June 27, John "Robert" Thorson will retain his responsibilities as Treasurer and Treasury Division Manager. Thorson served as the company's CFO from 2005 through 2019, and from March 2023 through June 2024.

12:02 EDT Sunnova Energy falls -7.9% - Sunnova Energy is down -7.9%, or -52c to $5.99.

12:01 EDT Nike falls -19.3% - Nike is down -19.3%, or -$18.20 to $76.00.

12:01 EDT ADC Therapeutics rises 9.6% - ADC Therapeutics is up 9.6%, or 27c to $3.08.

11:46 EDT Sanofi: Fexalimab Ph2 data showed lower key biomarker of nerve cell damage - Sanofi's CD40L monoclonal antibody, frexalimab, reduced a key biomarker associated with multiple sclerosis nerve cell damage in patients with relapsing MS, supporting the rationale for this novel mechanism in MS phase 3 studies aiming to delay disability progression, the company announced. New phase 2 results showed significant reduction in plasma levels of neurofilament light chain after one year of treatment, a biomarker of nerve cell damage that is typically elevated in people living with MS. These data were presented at the 10th Congress of the European Academy of Neurology in Helsinki, Finland. Ninety-seven percent of the study participants from the initial 12-week double-blind period entered the open-label extension of the phase 2 study, and 87% remained in the study by the 48-week cut-off. NfL biomarker results from the phase 2 study showed: Plasma NfL levels were similar across all study groups at baseline and were reduced across all four treatment groups by week 48. Participants receiving high-dose frexalimab experienced a 41% reduction in plasma NfL levels from baseline, the greatest NfL level reduction across the four treatment groups. Participants receiving low-dose frexalimab experienced a 35% reduction in plasma NfL levels from baseline. Participants in the placebo-high group who switched to high-dose frexalimab at week 12 experienced a 24% reduction in plasma NfL levels from baseline and by 39% from week 12 when switched from placebo to high-dose frexalimab. Reference Link

11:36 EDT J&J: Nipocalimab Phase 3 trial demonstrates sustained disease control - Johnson & Johnson announced "positive" results from the nipocalimab Phase 3 Vivacity-MG3 study in patients with generalized myasthenia gravis. Patients treated with nipocalimab plus standard of care achieved superiority over placebo plus SOC as measured by the primary endpoint of improvement in the MG-ADL score from baseline over 24 weeks. These data are included in a presentation and are among eight abstracts that Johnson & Johnson will present at the European Academy of Neurology 2024 Congress and will be included in submissions to regulatory authorities later this year. The double-blind placebo-controlled study enrolled a broad population of anti-AChR+, anti-MuSK+ and/or anti-LRP4+ patients, which account for approximately 95 percent of the gMG patient population.2 Patients receiving nipocalimab plus SOC improved by 4.70 points on the MG-ADL, significantly more than the 3.25 point improvement from baseline observed with placebo plus SOC from baseline over Weeks 22, 23 and 24. For someone living with gMG, a 1- to 2-point change on MG-ADL may be the difference between normal eating and frequent choking on food, or shortness of breath at rest and being on a ventilator.3 In addition to achieving this primary endpoint, critical secondary endpoints were also met: Improvement in strength and function of different muscle groups, as measured by QMGd, was significantly greater with nipocalimab plus SOC compared with placebo plus SOC over Weeks 22 and 24.MG-ADL response was significantly greater in nipocalimab plus SOC compared with placebo plus SOC over Weeks 22, 23 and 24, further underscoring the potential of treatment with nipocalimab to mitigate the impact of gMG on a patient's day-to-day life. Safety and tolerability were consistent with other nipocalimab studies. The overall incidence of adverse events, serious adverse events and adverse events leading to discontinuation was similar to that in the placebo plus current SOC group.

11:20 EDT Tiziana Life Sciences receives $3.4M in non-dilutive funding - Tiziana Life Sciences announced that it had received non-dilutive funding of $3.4M. Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences commented, "Tiziana is pleased to receive $3.4M in non-dilutive funding to support our ongoing Phase 2 trial of intranasal foralumab in non-active secondary progressive multiple sclerosis as well as our work in Alzheimer's Disease. We continue to explore all avenues to pursue further non-dilutive funding in the near term."

10:50 EDT Blackstone completes privatization of AIR Communities for $10B - Blackstone (BX) and Apartment Income REIT Corp. (AIRC) announced that Blackstone Real Estate Partners X has completed its previously announced acquisition of all outstanding common shares of AIR Communities for $39.12 per share in an all-cash transaction valued at approximately $10B, including the assumption of debt.

10:31 EDT Hall of Fame Village awarded $9.8M grant from state of Ohio - Hall of Fame Resort & Entertainment announced that Hall of Fame Village has been awarded a $9.8M grant from the State of Ohio's One Time Strategic Community Investments in support of the development of the Village. "We continue to be grateful for the tremendous leadership of Senate President Pro Tempore Kirk Schuring, Representative Scott Oeslager as well as Senate President Matt Huffman, and the many other civic leaders within the State of Ohio for their continued support of our Hall of Fame Village project," shared Hall of Fame Resort & Entertainment President and CEO Michael Crawford. "The award of this grant speaks to the state's belief in the social and economic impact we are already having in our community and throughout northeast Ohio."

10:03 EDT Rio Tinto to install carbon free aluminium smelting cells using ELYSIS license - Rio Tinto (RIO) will install carbon free aluminium smelting cells at its Arvida smelter in Quebec, Canada, using the first technology licence issued by the ELYSIS joint venture. This investment will support the ongoing development of the ELYSIS technology and allow Rio Tinto to build expertise in its installation and operation. Rio Tinto will design, engineer, and build a demonstration plant equipped with ten pots operating at 100 kiloamperes. The plant will be owned by a new joint venture in which Rio Tinto and the Government of Quebec, through Investissement Quebec, will invest $179M and $106M respectively as equity partners, for a total investment of $285M. This facility will use the same technology that has been successfully demonstrated at the ELYSIS Industrial Research and Development Center in Saguenay-Lac-St-Jean. ELYSIS joint venture partner Alcoa (AA) will have the option to purchase from Rio Tinto a portion of the aluminium produced over the first four years at the Arvida demonstration plant through an offtake agreement. The joint venture is continuing its research and development program to scale up the ELYSIS technology and has completed the construction of larger prototype 450 kA cells at the end of an existing potline at Rio Tinto's Alma smelter. ELYSIS has begun commissioning these industrial prototype cells, with the start-up sequence set to begin in 2024.

10:01 EDT Oscar Health falls -6.8% - Oscar Health is down -6.8%, or -$1.20 to $16.45.

10:00 EDT Nike falls -17.3% - Nike is down -17.3%, or -$16.31 to $77.88.

10:00 EDT Tilly's rises 5.8% - Tilly's is up 5.8%, or 31c to $5.64.

09:48 EDT Foot Locker falls -5.0% - Foot Locker is down -5.0%, or -$1.27 to $24.25.

09:48 EDT Nike falls -16.3% - Nike is down -16.3%, or -$15.35 to $78.84.

09:47 EDT Peabody Energy rises 4.8% - Peabody Energy is up 4.8%, or $1.03 to $22.62.

09:40 EDT Wheeler Real Estate Investment Trust trading resumes

09:30 EDT Pyxis Tankers announces closing of modern dry bulk vessel joint venture - Pyxis Tankers announced that it has closed its previously announced dry bulk vessel joint venture with an entity related to its Chairman and Chief Executive Officer, that was newly formed to acquire, own and operate, the "Konkar Venture", a 2015 built 82,099 dwt Kamsarmax carrier. The Company invested $7.3 million in cash and will issue 267,857 restricted common shares for a 60% ownership interest in the joint venture. After the acquisition of the vessel, including payment of transaction fees and expenses and application of vessel working capital, the Company's consolidated total cash is estimated to be approximately $43.0 million, inclusive of restricted cash of $2.2 million, with total funded debt of approximately $89.0 million.

09:18 EDT Hyatt acquires me and all hotels brand from Lindner Hotels, terms undisclosed - Hyatt announced that a Hyatt affiliate has acquired the me and all hotels brand from Lindner Hotels in an effort to unlock growth in new European markets and build on Hyatt's momentum in the region. This move builds on the collaboration that Hyatt and Lindner entered into in 2022, which increased Hyatt's brand footprint in Germany and Europe, with the subsequent integration of most Lindner Hotels & Resorts and me and all hotels into the World of Hyatt loyalty program. Following the transaction, me and all hotels, which is currently a nested brand within Hyatt's JdV by Hyatt brand, will become a standalone brand within Hyatt's global lifestyle portfolio, which has quintupled in rooms between 2017 and the end of 2023. The transaction closed on June 28.

09:04 EDT Elevai Labs subsidiary announces Elevai S-Series hair, scalp care - ELEVAI LABS announces the introduction of the Elevai S-Series hair and scalp care product line through Elevai Skincare, a subsidiary of Elevai Labs.

09:03 EDT MoneyHero announces strategic partnership with Jirnexu - MoneyHero announced the signing of a strategic transaction with Malaysian fintech company, Jirnexu Pte., parent company of Jirnexu Sdn. Bhd., the operator of RinggitPlus, Malaysia's largest operating B2C platform. Through this transaction, MoneyHero's B2C brand 'CompareHero', operating exclusively in Malaysia, its website, domain names, select user data, and IP rights will be acquired by Jirnexu Sdn. Bhd. When the transaction is completed, the CompareHero brand will continue in operation under the world-class systems of Jirnexu Sdn. Bhd. moving forward. In connection with this transaction, MoneyHero will retain an equity position in Jirnexu Pte. Ltd. Terms of the deal, expected to close in early July 2024, are confidential.

09:01 EDT IZEA announces $5M share repurchase program - IZEA Worldwide announced that its Board of Directors has authorized a share repurchase program under which the company may repurchase up to $5 million worth of its common stock from time to time, subject to market conditions and the Company's insider trading windows. A special committee consisting of independent Board members has been formed to authorize each individual buyback.

09:01 EDT Fabric acquires MeMD from Walmart, terms not disclosed - Fabric, a healthcare technology company and care enablement system, announced the acquisition of MeMD from Walmart. MeMD is a leading provider of virtual behavioral, urgent, and primary care benefits for 30,000 corporate, institutional, and health plan partners and 5 million members. This acquisition advances Fabric's employer strategy and marks a significant milestone in the team's mission to power boundless, high-quality care for consumers across the nation.

08:55 EDT Haynes names Losch III as Chief Operating Officer - Haynes International announced Marlin Losch III has been named Chief Operating Officer of Haynes International, effective July 1st. In this newly created position, Losch will have responsibility for all commercial and operational activities for the Company. Losch will report directly to Michael Shor, President and Chief Executive Officer of Haynes.

08:43 EDT Dyadic, Proliant Health and Biologicals enter partnership for albumin - Dyadic International announced that they have entered into a development and commercialization partnership with Proliant Health and Biologicals. According to the terms of the agreement, Dyadic will receive an upfront milestone payment of $1.5MM and have agreed to a share of profits received by PHB from the sale of animal-free recombinant albumin products produced using Dyadic's filamentous fungal microbial platforms. A portion of the upfront milestone payment will be allocated to the technology transfer and commercialization effort. The initial focus of the partnership will be the commercialization of recombinant human serum albumin products, with the anticipated launch of the first product in the first half of 2025.

08:42 EDT Reborn Coffee collaborates with Hagerty Garage + Social - Reborn Coffee announces its collaboration with Hagerty Garage + Social of Miami, FL, to commemorate the first-ever Hagerty Drivers Club Days, which was a three-day period of automotive events recently hosted by the Hagerty Drivers Club to celebrate its Hagerty Drivers Club members and the company's 40th anniversary.

08:41 EDT Cheetah Net Supply Chain Service to move headquarters to Los Angeles - Cheetah Net Supply Chain Service intends to relocate its headquarters from North Carolina to Los Angeles. The Company anticipates that this relocation will open significant opportunities in supply chain finance for Cheetah Net. The Company cited several strategic reasons for this move: Proximity to Ports: LA is the home to the Port of LA and the Port of Long Beach, which are among the busiest ports in the world. This proximity can significantly reduce shipping costs and transit times. Infrastructure and Logistics: LA has well-developed infrastructure and logistics networks that support international and domestic trade. This includes access to major highways, railways, and airports, all to facilitate the movement of goods. Market Access: LA provides ready access to a large consumer market, which is advantageous for establishing a distribution hub and expanding the customer base. Business Environment: LA offers a vibrant business environment with a diverse economy, access to skilled labor, and a supportive ecosystem for international trade and commerce. Quality of Life: LA's climate, lifestyle, and amenities make it a desirable location for attracting and retaining qualified and motivated employees. In LA, Cheetah Net aims to enhance its supply chain financial services to provide support to upstream and downstream enterprises and traders. Cheetah Net's offerings will include financial services such as loans, short-term bridge loans, and local trade and business transaction bridge loans. The Company believes that this move will enable Cheetah Net to better serve the dynamic needs of the supply chain market.

08:40 EDT Intelligent Bio Solutions completes in-clinic portion of PK study - Intelligent Bio Solutions announced the completion of the in-clinic portion of its pharmacokinetic study, a core component of the Company's clinical study plan for its 510(k) pathway for regulatory approval. Dosing and sampling of the second cohort for the study concluded on Thursday, June 27, 2024, marking the completion of this phase and the end of the in-clinic portion of the study. The PK study aims to demonstrate that the Company's fingerprint sweat collection method provides results comparable to those from other specimen matrices, such as blood, saliva, and urine. The specimens are currently being analyzed using validated, traceable liquid chromatography/mass spectrometry methods. The subsequent data analysis from the PK trial will compare the detection of opiates in fingerprint sweat versus blood, saliva, and urine specimens. The Company expects to complete the full PK study in the third calendar quarter of 2024.

08:39 EDT Atossa announces updated protocol for trial of (Z)-Endoxifen with abemaciclib - Atossa Therapeutics (ATOS) announced protocol changes in the previously initiated study to evaluate Atossa's proprietary (Z)-endoxifen in combination with abemaciclib, a cyclin-dependent kinase 4/6 inhibitor marketed by Eli Lilly and Company (LLY). The study is investigating the combination as a neoadjuvant treatment in women with newly diagnosed Estrogen Receptor positive / Human Epidermal Growth Factor Receptor 2 negative breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. Based on accumulating data from the ongoing Phase 2 EVANGELINE study, the dose of (Z)-endoxifen in the combination study has been increased from 40 mg to 80 mg once daily. The change in study dose was determined following a review of safety, efficacy and pharmacokinetic data from participants currently enrolled in the 80 mg PK run-in cohort of the EVANGELINE study. The EVANGELINE study is enrolling premenopausal women with ER+/HER2- breast cancer. The study began with a 40 mg pharmacokinetic run-in cohort. Data from this cohort, which was presented at the 2024 American Association for Cancer Research Annual Meeting, showed encouraging efficacy and an extremely favorable safety profile compared to currently approved endocrine therapies. Efficacy was measured by both reduction in Ki-67, a cellular marker for proliferation that indicates how fast the tumor is growing, and response. Participants treated for a total of 24-weeks experienced an average reduction in Ki-67 of 92% and an average target lesion decrease of 37%. The study is now enrolling an 80 mg PK cohort, which is expected to deliver the optimal drug concentrations required to fully target PKCbeta1 inhibition and further enhance (Z)-endoxifen's antitumor efficacy. Additionally, the combination study will now enroll approximately 80 participants across two 40-participant cohorts. Both cohorts will include pre-and-menopausal women who will receive 80 mg (Z)-endoxifen once daily in combination with 150 mg abemaciclib twice daily for up to 24-weeks prior to surgery. Premenopausal women in the second cohort will also receive ovarian function suppression. Increasing the number of study participants was done to ensure a statistically significant number of menopausal and premenopausal women are enrolled in each cohort. The addition of OFS in premenopausal women enrolled in the second cohort of the study will allow for a direct comparison of safety and efficacy among the two treatment groups. This data is expected to further validate the growing body of evidence that (Z)-endoxifen is safe and highly efficacious in premenopausal women without the need for OFS. Under the terms of the study agreement, Atossa and Eli Lilly and Company are each responsible for supplying their respective study drugs.

08:35 EDT Procaps Group chairman Ruben Minski resigns, Jose Minski succeeds - Procaps Group announced that Ruben Minski has resigned from his role as executive chairman of the board, effective June 30. Minski will continue to serve as a member of the board of directors. The board of directors of the company has appointed Jose Minski, currently a member of the board and chair of the M&A Committee, as the new chairman of the board.

08:26 EDT Rivian Automotive targets long-term adjusted EBITDA margin in 'high teens' - Targets long-term gross margin about 25% and free cash flow margin of about 10%. Affirms FY24 production guidance of 57K vehicles. Sees Q2 production 9.1K-9.3K vehicles, with deliveries at 13.0K-13.3K. Comments taken from Investor Day presentation slides yesterday. Reference Link

08:18 EDT Xiao-I partners with leading telecommunications provider - Xiao-I is proud to announce a partnership with a leading telecommunications provider to deploy its advanced AI Chatbot solution in Q2. This strategic collaboration aims to transform the provider's customer service operations by enhancing service efficiency, reducing operational costs, and providing 24/7 personalized support. The implementation of Xiao-I's AI Chatbot on WhatsApp for a leading telecommunications provider represents a significant advancement in customer service. This deployment not only addresses key challenges but also sets a new standard for the industry. The chatbot's intuitive design, zero-code deployment, and robust scalability highlight Xiao-I Corporation's expertise in delivering cutting-edge AI solutions.

08:11 EDT VCI Global announces secondary listing on Frankfurt Stock Exchange - VCI Global announces its secondary listing on the Frankfurt Stock Exchange under the ticker symbol "H0T" in the Open Market. This strategic move marks a significant step in enhancing VCIG's global presence and expanding its shareholder base to European investors. This new listing underscores VCIG's commitment to innovation and growth in key sectors, aiming to capture new opportunities in Europe's dynamic business landscape.

08:09 EDT NRx Pharmaceuticals to proceed with two new NDAs in 2024 - NRx Pharmaceuticals announced that advice from regulatory counsel, which includes former senior officials from the Food and Drug Administration, supports filing two New Drug Applications in 2024: an application for Accelerated Approval for NRX-101 to treat bipolar depression in patients with akathisia and an application for approval of NRX-100 for treatment of suicidal depression. Gaining these approvals has the potential to yield more than $150 in revenue per NRXP share in the near term, at current share count.

08:06 EDT Contango Ore announces HighGold Mining shareholder approval of arrangement - Contango Ore announced that HighGold Mining shareholders and optionholders of HighGold have overwhelmingly approved the previously announced arrangement involving HighGold and the company at HighGold's special meeting held on June 27. At the meeting, the special resolution approving the arrangement was approved by 93.7% of the HighGold shareholders and 94.4% of the HighGold Securityholders voting as a single class, and 93.6% of the HighGold shareholders, excluding votes required to be excluded pursuant to Multilateral Instrument 61-101 - Protection of Minority Security Holders in special transactions. Accordingly, the HighGold Securityholder approval required to proceed with the arrangement has been obtained. HighGold will seek a final order approving the arrangement from the Supreme Court of British Columbia on July 2. Subject to the satisfaction of certain customary closing conditions, the parties currently expect the closing of this acquisition to complete on or around July 9.

08:05 EDT Rhythm Pharmaceuticals receives positive CHMP opinion for IMCIVREE - Rhythm Pharmaceuticals announced that the European Medicines Agency's, EMA, Committee for Medicinal Products for Human Use, CHMP, has adopted a positive opinion recommending the marketing authorization for IMCIVREE include children between 2 and younger than 6 years old with obesity due to Bardet Biedl syndrome or pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency. The CHMP opinion on the marketing authorization to include patients as young as 2 years old now will be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicinal products in the European Union. A final decision on the application to expand the marketing authorization for setmelanotide is anticipated in the second half of 2024.

08:03 EDT GE Aerospace T901 engines accepted by U.S. Army for Black Hawk testing - GE Aerospace announced the acceptance of two T901-GE-900 engines by the U.S. Army for the Improved Turbine Engine Program's UH-60 Black Hawk integration and testing. The next-generation rotorcraft engines were unboxed during a ceremony at Sikorsky's facility in West Palm Beach, Florida.

07:58 EDT AeroVironment targets long-term total revenue growth of over 20% - Targets organic revenue growth of 10%-15%, R&D Investment up 8%-10%, and longer-term adjusted EBITDA growth of 22%-24%. Comments taken from investor day presentation yesterday.

07:37 EDT Fisker issues voluntary recall for 12,523 vehicles for outer door handles - Fisker announced that it has issued a voluntary recall for 12,523 vehicles in North America and Europe for an issue involving the outer door handles on 2023-2024 Fisker Ocean vehicles. Fisker is issuing a voluntary recall for 8,204 vehicles in the U.S., 513 vehicles in Canada, and 3,806 vehicles in Europe. The company estimates that 2.5% of vehicles could have the defect. The door handles on the Fisker Ocean may become stuck due to a malfunctioning mechanism. Addressing this malfunction promptly is essential to ensure the safety and accessibility of the vehicle for its passengers. Fisker intends to perform a thorough inspection of all four side door handles on each vehicle utilizing a specialized force checking tool provided by the outer door handle supplier. If the force checking tool indicates any side door handle as "Not Okay," the outer door handle will be replaced. This proactive measure ensures that all door handles meet the required safety and operational standards, thereby enhancing the overall reliability and functionality of the vehicle's entry system. The National Highway Traffic Safety Administration, or NHTSA, and Transport Canada, or TC, are in the process of posting these recall notices on their websites. Fisker expects to complete the door-handle evaluations and repairs update process as soon as possible. The company informed its dealer partners of these recall actions on June 17 and will notify owners by August 30.

07:35 EDT Rocket Pharmaceuticals announces FDA complete response letter for Kresladi - Rocket Pharmaceuticals announced a regulatory update for Kresladi, a lentiviral vector-based gene therapy to treat severe leukocyte adhesion deficiency-I, or LAD-I. The FDA has issued a complete response letter, or CRL, in response to Rocket's biologics license application for Kresladi wherein the FDA requested limited additional Chemistry Manufacturing and Controls, or CMC, information to complete its review. Rocket met with FDA senior leaders from Center for Biologics Evaluation and Research to align on the limited scope of additional CMC information needed to support the approval of Kresladi as quickly as possible. Positive top-line data from the global Phase 1/2 study of Kresladi demonstrated 100% overall survival at 12 months post-infusion for all nine LAD-I patients with 18 to 42 months of available follow-up. Data also showed large decreases compared with pre-treatment history in the incidences of significant infections, combined with evidence of resolution of LAD-I-related skin lesions and restoration of wound repair capabilities. All primary and secondary endpoints were met, and Kresladi was well tolerated in all patients with no treatment-related serious adverse events.

07:32 EDT DeFi Technologies subsidiary Valour launches two ETPs - DeFi Technologies announces that its subsidiary Valour has launched two new ETPs: the Valour CORE ETP and the Valour Hedera ETP, on the Spotlight Stock Market in Sweden. These launches mark the first ETP offerings for Spotlight, as well as a significant milestone in Valour's mission to provide retail and institutional investors with secure and simple access to leading digital assets.

07:15 EDT Can-Fite partner reports results from osteoarthritis multicenter clinical study - Can-Fite BioPharma announced that its veterinary partner Vetbiolix reported results in an osteoarthritis multicenter clinical study in dogs treated with Piclidenoson. Vetbiolix, Can-Fite's veterinary commercialization partner which is covering all costs associated with veterinary clinical development, concluded the study interim analysis. After Piclidenoson proved efficacious, Vetbiolix can exercise the option to enter into a full in license agreement with Can-Fite and be obligated to pay Can-Fite upfront and milestone payments, in addition to royalties on sales upon regulatory approval. The study looked at the effect of 90 days treatment with Piclidenoson at 100 microgram/kg and 500 microgram/kg twice daily orally in dog patients with osteoarthritis. The primary objective was the Liverpool OsteoArthritis in Dogs, or LOAD, questionnaire for the assessment of symptoms severity evaluated on dog's mobility. The secondary objectives included Visual Analog Scale for pain assessment by pet parents and Numerical Rating Score for lameness and pain assessment by the veterinarian. The study reached the primary and secondary end points with a dose and time dependent inhibitory effect of piclidenoson on LOAD and VAS and NRS, demonstrating significant improvement in clinical status and decrease in pain in the 500 microgram/kg dose. The canine osteoarthritis market is projected to reach $3B by 2028. There is a clear need in the market for a safe and effective canine osteoarthritis drug.

07:11 EDT Mind Medicine to be included in Russell 2000, 3000 Indexes - Mind Medicine announced that as part of the annual reconstitution of the Russell stock indexes, the company will be included in the Russell 2000 Index and the broad-market Russell 3000 Index, effective immediately.

07:09 EDT Moderna announces positive CHMP opinion for marketing authorization of mRESVIA - Moderna announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the granting of marketing authorization in the European Union for mRESVIA, an mRNA respiratory syncytial virus vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. Following the CHMP's positive opinion, the European Commission will adopt a decision on the authorization of mRESVIA. The CHMP positive opinion for mRESVIA is based on positive data from the Phase 3 clinical trial ConquerRSV, a global study conducted in approximately 37,000 adults ages 60 years or older in 22 countries. The primary analysis with 3.7 months of median follow-up found a vaccine efficacy against RSV lower respiratory tract disease of 83.7%, with these results published in The New England Journal of Medicine. In a supplementary analysis with 8.6 months of median follow-up, mRNA-1345 maintained durable efficacy, with sustained VE of 63.3% against RSV-LRTD, including two or more symptoms. VE was 74.6% against RSV-LRTD with greater than or equal to2 symptoms, including shortness of breath, and VE was 63.0% against RSV LRTD including three or more symptoms. The stringent statistical criterion of the study, a lower bound on the 95% CI of greater than20%, continued to be met for both endpoints. The most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia, and arthralgia.

07:06 EDT Verve Therapeutics appoints Nia Tatsis, Jodie Morrison to board - Verve Therapeutics (VERV) announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its board of directors. Dr. Tatsis currently serves as executive vice president, chief regulatory and quality officer, of Vertex Pharmaceuticals (VRTX). Ms. Morrison currently serves as CEO and director of Q32 Bio (QTTB).

07:04 EDT 23andMe, Nightingale Health collaborate to pilot blood biomarker panel - 23andMe Holding and Nightingale Health announced a strategic collaboration to pilot Nightingale Health's clinically-validated and cost-effective blood metabolomics panel with a cohort of 23andMe members. Nightingale's Remote Health Check accurately measures dozens of biomarkers from a single blood sample, including cholesterols, apolipoproteins and fatty acids like omega-3. Many of these blood biomarkers have established clinical relationships to disease and can help guide important lifestyle interventions - such as diet and exercise. This pilot marks an important milestone in making blood testing more efficient and accessible. 23andMe currently offers its annual members the option for blood testing and provides interactive tools like HealthTracks, a feature that incorporates customer lifestyle choices into calculating a lifetime risk of disease. Blood biomarkers may improve the accuracy of these predictions and provide more direct insight into the kinds of interventions that may be most impactful to a customer's health. As part of the pilot, 23andMe will offer up to 5,000 23andMe+ Premium and Total Health members the opportunity to receive blood testing through Nightingale's Remote Health Check at no cost to them. The pilot will evaluate customer feedback around blood testing, at-home sample collection, and the utility of the data when coupled with 23andMe's established personal genetics products.

07:02 EDT Amwell announces 1-for-20 reverse stock split - Amwell announced that its Board of Directors has approved a 1-for-20 reverse stock split of its Class A common stock, Class B common stock and Class C common stock, that is expected to become effective on July 10, 2024 at 5:00 p.m. EDT. The shares of the Company's Class A common stock are expected to begin trading on the New York Stock Exchange on a split-adjusted basis at the market open on July 11, 2024. No change will be made to the trading symbol for the Company's shares of Class A common stock, "AMWL", in connection with the Reverse Split. The Company expects that the Reverse Split will allow the Company to regain compliance with the $1.00 minimum average closing price requirement of the NYSE. The new CUSIP number for the Class A common stock following the Reverse Split will be 03044L 204.

07:01 EDT Regeneron announces positive CHMP opinion for odronextamab - Regeneron Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory follicular lymphoma or R/R diffuse large B-cell lymphoma, after two or more lines of systemic therapy. The European Commission is expected to announce a final decision in the coming months. The positive CHMP opinion is supported by results from the Phase 1 ELM-1 and pivotal Phase 2 ELM-2 trials, which demonstrated robust, durable response rates and an acceptable safety profile of odronextamab in adults with R/R FL or R/R DLBCL. In a pooled safety population, the most common serious adverse reactions were cytokine release syndrome, pneumonia, COVID-19 and pyrexia. The EMA previously granted odronextamab Orphan Designation for both FL and DLBCL. Odronextamab is currently under clinical development and has not been approved by any regulatory authority.

07:01 EDT Asset Entities announces 1-for-5 reverse stock split - Asset Entities announced a 1-for-5 reverse stock split of its class A common stock, $0.0001 par value per share, and its class B common stock, $0.0001 par value per share. The Reverse Stock Split is intended to enable the Company to regain compliance with the minimum bid price requirement for continued listing on Nasdaq.

06:58 EDT Apellis: CHMP adopts negative opinion on MAA of intravitreal pegcetacoplan - Apellis Pharmaceuticals announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion on the marketing authorization application of intravitreal pegcetacoplan for the treatment of geographic atrophy. Notably, there were multiple dissenting votes by CHMP members to this opinion. Apellis plans to seek re-examination and expects a final opinion in the fourth quarter of 2024. This opinion followed an Ad Hoc Expert Group meeting, in which the experts agreed that size of GA lesion is an acceptable primary outcome measure for a trial in GA and that microperimetry is the best available functional measure in GA.

06:46 EDT Lindsay raises quarterly dividend to 36c from 35c per share - Lindsay announced that its Board of Directors has declared a regular quarterly cash dividend of 36c per share, payable August 30 to shareholders of record at the close of business on August 16. This quarterly cash dividend rate represents a 3% increase to the previous quarterly indicated rate of 35c per share. The new annual indicated rate is $1.44 per share, up from the previous annual indicated rate of $1.40 per share.

06:06 EDT PTC Therapeutics announces CHMP maintains Translarna negative opinion - PTC Therapeutics announced that the CHMP has issued a negative opinion on the renewal of the conditional marketing authorization of Translarna for the treatment of nmDMD. This opinion follows the return of the previously issued negative opinion by the European Commission for re-review. PTC plans to request re-examination of the opinion. The marketing authorization for Translarna remains in effect, pending the outcome of the re-examination procedure and subsequent EC ratification. Based on the timeline of these procedures, PTC expects Translarna to remain on the market through the end of 2024 even if the negative opinion is maintained and ratified. "We are disappointed that the CHMP has maintained its negative opinion on Translarna despite the request of the European Commission to consider the totality of evidence including the STRIDE real world evidence in a revised opinion," said Matthew Klein, CEO, PTC Therapeutics. "The Scientific Advisory Group convened as part of this most recent review procedure concluded that the evidence of significant efficacy provided by STRIDE 'should not be ignored.' This view of the CHMP expert committee is consistent with the view of DMD key opinion leaders worldwide. We will request re-examination of the CHMP opinion to ensure that we make every effort to maintain availability of Translarna on the market for as long as possible for boys and young men with nmDMD."

05:23 EDT Astera Labs to expand operations to India - Astera Labs announced its plan to expand operations to India. The new site to be opened in Bangalore later this year will tap into the region's rich engineering talent and establish a robust pipeline of cutting-edge interconnect technologies that enable AI architectures throughout the data center. The new India site will join Astera Labs' existing R&D centers in Santa Clara, California, Toronto and Vancouver, Canada, and Haifa, Israel.

05:15 EDT AbbVie gets CHMP opinion recommending marketing authorization of epcoritamab - AbbVie announced that the European Medicines Agency's, or EMA, Committee for Medicinal Products for Human Use, or CHMP, has adopted an opinion recommending the conditional marketing authorization of epcoritamab, the first and only T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more prior therapies. The European Commission decision on this indication for epcoritamab is anticipated later this year.